Zentalis Pharmaceuticals (ZNTL) Net Cash Flow (2019 - 2026)

Zentalis Pharmaceuticals' Net Cash Flow history runs 8 years deep, the most recent figure standing at -$4.1 million for Q1 2026.

• In Q1 2026, Net Cash Flow fell 150.64% year-over-year to -$4.1 million; the TTM figure through Mar 2026 stood at -$10.0 million (down 334.77% YoY), while the FY2025 annual figure was $2.1 million, down 63.95% from the prior year.
• Net Cash Flow for Q1 2026 stood at -$4.1 million, down from -$3.1 million in the prior quarter.
• The five-year high for Net Cash Flow was $230.3 million in Q2 2023, with the low at -$155.8 million in Q3 2023.
• The 5-year median for Net Cash Flow is -$3.1 million (2025), against an average of -$1.6 million.
• Peak annual rise in Net Cash Flow reached 846.56% in 2023, while the deepest fall reached 16057.34% in 2023.
• Zentalis Pharmaceuticals' Net Cash Flow stood at $518000.0 in 2022, then slumped by 16057.34% to -$82.7 million in 2023, then soared by 91.02% to -$7.4 million in 2024, then soared by 58.53% to -$3.1 million in 2025, then tumbled by 32.11% to -$4.1 million in 2026.
• Business Quant data shows ZNTL's Net Cash Flow at -$4.1 million in Q1 2026, -$3.1 million in Q4 2025, and $1.5 million in Q3 2025.